drugset

drugset / Trial / NCT01238094

Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer

NCT01238094 ↗

Phase 3 Unknown 258 enrolled Samsung Medical Center

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare 2nd line XELIRI/FOLFIRI + simvastatin vs XELIRI/FOLFIRI + placebo.

Timeline

Start: 2010-04
Primary completion: 2013-11
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Simvastatin	Small molecule	40 mg	—

Indications